BMBrenda Melendez

Brenda Melendez

*This is an algorithmically generated author record based on publicly available information.

Brenda Melendez has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Collene Jeter

    The University of Texas MD Anderson Cancer Center 14 Division of VP, Research, Department of Epigenetics and Molecular Carcinogenesis Houston, Texas

    1 shared publication
  • Deena M. Scoville

    Department of Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA

    1 shared publication
  • Diana Moreno

    Department of Gynecologic Oncology

    1 shared publication
  • Elizabeth M. Whitley

    Department of Veterinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    1 shared publication
  • Hyun-Eui Kim

    Affiliations Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, United States of America, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas, United States of America

    1 shared publication
  • Jae-Wook Jeong

    Department of Obstetrics, Gynecology and Women's Health University of Missouri Columbia Missouri USA

    1 shared publication

Latest Publications

  • Open Access

    Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome–associated MSH2-deficient endometrial cancer

    by Mikayla Borthwick Bowen, Brenda Melendez, Qian Zhang, Diana Moreno, Leah Peralta, Wai Kin Chan, Collene Jeter, Lin Tan, M. Anna Zal, Philip L. Lorenzi, et al.

    Lynch syndrome (LS), caused by inherited mutations in DNA mismatch repair genes, including MSH2 , carries a 60% lifetime risk of developing endometrial cancer (EC). Beyond hypermutability, mechanisms driving LS-associated EC (LS-EC) remain unclear. We investigated MSH2 loss in EC pathogenesis using a mouse model ( PR-Cre Msh2 LoxP/LoxP , abbreviated Msh2KO), primary cell lines, human tissues, and human EC cells with isogenic MSH2 knockdown. By 8 months, 58% of Msh2KO mice developed endometrial atypical hyperplasia (AH), a precancerous lesion. At 12–16 months, 50% of Msh2KO mice exhibited either AH or ECs with histologic similarities to human LS-ECs. Transcriptomic profiling of EC from Msh2KO mice revealed mitochondrial dysfunction–related pathway changes. Subsequent studies in vitro and in vivo revealed mitochondrial dysfunction based on 2 mechanisms: mitochondrial content reduction and structural disruptions in retained mitochondria. Human LS-ECs also exhibited mitochondrial content reduction compared with non-LS-ECs. Functional studies demonstrated metabolic reprogramming of MSH2-deficient EC, including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression. These findings identified mitochondrial dysfunction and metabolic disruption as consequences of MSH2 deficiency in EC. Mitochondrial and metabolic aberrations should be evaluated as biomarkers for endometrial carcinogenesis or risk stratification and represent potential targets for cancer interception in women with LS.